Focus on injectables in the ‘Pharmaceutical Post’


marketing interview - october 2021 - press

Severine Duband, our Marketing Director was interviewed by the journalist of the ‘Pharmaceutical Post’, to talk about Symbioze and how we developed the product.

The main challenge for manufacturers is to design an administration system that can deliver complex drugs without compromising on the effectiveness integrity of the formulation.

Severine Duband, Marketing Direcctor

COVID-19 accelarate the trend of avoiding visits to the hospital or to other care centres, to limit the exposure to the virus. Based on that, companies in the pharmaceutical industry are looking for self administration device. With that in mind, Nemera’s team are currently focusing on two main directions: increasing the volumes injected and support the gradual transition from IV administration drugs towards subcutaneous administration.

The current period is therefore under the sign of many projects and new launches, while taking into account the strict quality requirements on new devices designed for high added value treatments. With several work directions, large volume to be administered, sensitivity to proteins, simplicity of use, research for ergonomics, or even connected health.

In response, Nemera has recently introduced its new wearable injector device – Symbioze – whose innovative concept had been presented at Pharmapack Europe and CPhI Worldwide.

To read the full magazine : HERE

To read Nemera’s interview: HERE

About Nemera
As a world-leading drug delivery device solutions provider, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy. We are a holistic partner and help our customers succeed in the sprint to market of their combination products. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards. Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission.
For more information, visit

Latest News